Dare Bioscience

US Biotech Companies Shift Clinical Trials Abroad Amid FDA Uncertainty

- Several US biotech companies are considering conducting early-stage clinical trials outside the United States due to growing concerns about FDA stability following recent leadership changes and staff departures. - The shift toward European and Australian markets for initial trials represents a significant change in traditional drug development pathways, potentially costing companies millions in additional expenses. - While large pharmaceutical companies report no disruption in FDA interactions, smaller biotechs express concern that regulatory delays could threaten their survival in an already challenging funding environment.